Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1...read more
Two sizable IPOs priced this week, joined by seven SPACs. Ten IPOs and eight SPACs submitted initial filings. Medical supplies giant Medline (MDLN) priced its upsized IPO above the midpoint to raise $6.3 billion at a $38.7 billion market cap. The company is ...read more
MiniMed Group, a carve-out of Medtronic's diabetes management devices and technology business, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Being carved out of Medtronic, MiniMed focuses on integrated diabetes...read more
US IPO Week Ahead: Markets set for a quiet week after year’s first sizable IPO
...read more
US IPO Week Ahead: Aktis Oncology set to open 2026 IPO Market
Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1 ...read more
US IPO Weekly Recap: Medline and Andersen soar ahead of Christmas holiday
Two sizable IPOs priced this week, joined by seven SPACs. Ten IPOs and eight SPACs submitted initial filings. Medical supplies giant Medline (MDLN) priced its upsized IPO above the midpoint to raise $6.3 billion at a $38.7 billion market cap. The company is ...read more
Medtronic diabetes business carve-out MiniMed Group files for a $100 million IPO
MiniMed Group, a carve-out of Medtronic's diabetes management devices and technology business, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Being carved out of Medtronic, MiniMed focuses on integrated diabetes...read more